PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Grigg, Claud; Rizvi, Naiyer A.

doi:10.1186/s40425-016-0153-x

Table 3 Response rates to anti-PD-1/PD-L1 antibodies in NSCLC and selected malignancies according to PD-L1 positivity

From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Study	Antibody	Tumor type	PD-L1 cutoff	N	Response (%)
Nivolumab
Topalian et al. [10]	5H1	Multiple	≥5 %	25	36
Topalian et al. [10]	5H1	Multiple	<5 %	17	0
Gettinger et al. [11]	28-8	NSCLC	≥5 %	33	15
Gettinger et al. [11]	28-8	NSCLC	<5 %	35	14
Rizvi et al. [13]	28-8	Squamous NSCLC	≥5 %	25	24
Rizvi et al. [13]	28-8	Squamous NSCLC	<5 %	51	14
Brahmer et al. [14]	28-8	Squamous NSCLC	≥5 %	42	21
Brahmer et al. [14]	28-8	Squamous NSCLC	<5 %	75	15
Borghaei et al. [15]	28-8	Non-squamous NSCLC	≥5 %	95	34
Borghaei et al. [15]	28-8	Non-squamous NSCLC	<5 %	136	14
Hodi et al. [56]	28-8	Melanoma	≥5 %	18	44
Hodi et al. [56]	28-8	Melanoma	<5 %	23	13
Robert et al. [57]	28-8	Melanoma	≥5 %	74	53
Robert et al. [57]	28-8	Melanoma	<5 % or indet	136	33
Weber et al. [58]	28-8	Melanoma (ipilimumab refractory)	≥5 %	55	44
Weber et al. [58]	28-8	Melanoma (ipilimumab refractory)	<5 %	64	20
Larkin et al. [59]	28-8	Melanoma	≥5 %	80	58
Larkin et al. [59]	28-8	Melanoma	<5 %	208	41
Pembrolizumab
Garon et al. [16]	22C3	NSCLC	≥50 %	119	41
Garon et al. [16]	22C3	NSCLC	<50 %	237	13
Herbst et al. [17]	22C3	NSCLC	≥50 %	290	30
Herbst et al. [17]	22C3	NSCLC	1–49 %	400	10
Kefford et al. [60]	22C3	Melanoma	≥1 %	55	51
Kefford et al. [60]	22C3	Melanoma	<1 %	16	6
Puzanov et al. [61]	22C3	Melanoma (ipilimumab refractory)	≥1 %	193	26
Puzanov et al. [61]	22C3	Melanoma (ipilimumab refractory)	<1 %	93	15
Robert et al. [62]	22C3	Melanoma	≥1 %	896	NR (PFS HR 0.53)
Robert et al. [62]	22C3	Melanoma	<1 %	197	NR (PFS HR 0.67–0.76)
Atezolizumab (MPDL3280A)
Spigel et al. [63]	SP142	NSCLC	TC or IC ≥50 %	53	26
Spigel et al. [63]	SP142	NSCLC	TC or IC 5–49 %	84	14
Spira et al. [20, 64]	SP142	NSCLC	TC or IC ≥50 %	24	38
			TC or IC 1–49 %	69	12
			TC and IC <1 %	51	8
Besse et al. [65]	SP142	NSCLC	TC or IC ≥50 %	302	26
Besse et al. [65]	SP142	NSCLC	TC or IC 5–49 %	357	10
Powles et al. [66]	SP142	Urothelial	TC or IC ≥5 %	30	43
Powles et al. [66]	SP142	Urothelial	TC and IC <5 %	35	11
Rosenberg et al. [67]	SP142	Urothelial	TC or IC ≥5 %	100	26
			TC and IC 1–5 %	107	11
			TC and IC <1 %	103	8
Herbst et al. [21]	SP142	Multiple	TC or IC ≥50 %	33	46
			TC or IC 1–49 %	57	19
			TC and IC <1 %	60	13
Durvalumab (MEDI4736)
Rizvi et al. [68]	SP263	NSCLC	≥25 %	84	27
Rizvi et al. [68]	SP263	NSCLC	<25 %	92	5
Segal et al. [69]	SP263	HNSCC	≥25 %	22	18
Segal et al. [69]	SP263	HNSCC	<25 %	37	8
Avelumab (MSB0010718C)
Gulley et al. [70]	?	NSCLC	≥5 %	122	15
Gulley et al. [70]	?	NSCLC	<5 %	20	10
Apolo et al. [71]	?	Urothelial	≥5 %	10	40
Apolo et al. [71]	?	Urothelial	<5 %	22	9

Back to article page